MannKind Analyst Ratings
Oppenheimer Remains a Buy on MannKind (MNKD)
MannKind Buy Rating Affirmed by Analyst Thomas Smith on Strong Revenue Growth and Promising Clinical Developments
MannKind Analyst Ratings
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ), MannKind (MNKD) and Aquestive Therapeutics (AQST)
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)
MannKind Analyst Ratings
MannKind's Strong Q4 Financials and Therapeutic Portfolio Potential Merit a Buy Rating
MannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy Rating
MannKind (MNKD) Receives a New Rating From Cantor Fitzgerald
RBC Capital Sticks to Their Hold Rating for MannKind (MNKD)
MannKind (MNKD) Receives a Hold From RBC Capital
Strategic Deal Boosts MannKind's Financial Prospects: A Buy Rating Justified
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $7.5 Price Target
MannKind Analyst Ratings
MannKind Buy Rating Affirmed: Financial Strength and Market Potential Underpin Positive Outlook
Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)
Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating
Strong Q3 Results and Promising Clinical Progress: A Buy Rating for MannKind
Promising Growth and Expansion Potential Elevates MannKind to a Buy Rating